The Moscone Center
San Francisco, California, United States
27 January - 1 February 2018
Conference BO111
Mechanisms of Photobiomodulation Therapy XIII
Important
Dates
show | hide
Abstract Due:
17 July 2017

Author Notification:
25 September 2017

Manuscript Due Date:
5 January 2018

Conference
Cosponsors
Sponsored by:

Conference
Committee
show | hide
Conference Chairs
Program Committee
Program Committee continued...
  • Clark E. Tedford, LumiThera (United States)
  • Mei X. Wu, Harvard Medical School (United States), Wellman Ctr. for Photomedicine (United States)

Call for
Papers
Low levels of visible light (frequently red or near-infrared) can have significant therapeutic effects on multiple classes of diseases, injuries and medical dis¬orders. In particular it is effective for wound healing and pain control as well as reduction of inflammation and swelling. The recent acceptance of the MeSH term Photobiomodulation (PBM) Therapy by National Library of Medicine will facilitate more concerted efforts in the field at standardizing and optimizing many aspects of this exciting field.

It is believed that the primary intracellular chromophore that absorbs low levels of red and near-infrared light is cytochrome c oxidase, which is located in mitochondria. This absorption of energy may lead to increase in ATP synthesis and release of reactive oxygen species from the electron transport chain that can subsequently activate transcription factors and lead to cell proliferation and migration. A recently described extracellular mechanism involving activation of latent growth factor complex offers exciting new avenues to explore other PBM mechanisms.

Despite many reports of positive findings from experiments conducted in vitro, in animal models and in randomized controlled clinical trials, PBMT remains controversial. This likely is due to two main reasons; firstly the molecular mechanisms underlying the positive effects are incompletely understood. Secondly the complexity of rationally choosing among a large number of illumination parameters such as wavelength, fluence, power density, pulse structure and treatment timing has led to the pub¬lication of a number of negative studies as well as many positive ones.

This conference covers a field that is rapidly achieving a general level of acceptance in the medical and biomedical communities and will cover all of the important areas of PBMT research.

Contributed papers are solicited in the following areas (among others):
  • mechanistic studies and cellular chromophores
  • development of light sources for LLLT/PBMT (LED photomodulation; pulsed IR light therapy)
  • study of LLLT/PBMT dosimetry
  • in vitro research in mammalian cells
  • in vitro research in micro-organisms in culture
  • stimulation of wound healing and scar reduction in animal models
  • nerve regeneration and neural stimulation
  • prevention of ischemia-induced tissue death and regeneration.

    Well-controlled clinical trials in the following areas are strongly encouraged:
  • stimulation of wound healing such as non-healing ulcers
  • treatments for stroke and degenerative brain disease
  • pain reduction in post-surgical and neuralgia patients
  • dental applications
  • dermatology applications
  • reduction of pain and inflammation in arthritis and other orthopedic conditions
  • macular degeneration prevention
  • reduction of edema.
  • Back to Top